Biotin, real deficiency, the megadose trend, and the blood tests it skews

A 67-year-old woman with primary hyperparathyroidism and a history of partial parathyroidectomy took a daily 5 mg biotin supplement. Her bloodwork came back with a suppressed TSH (0.24 mIU/L), a low PTH (4.3 pg/mL, reference range 15 to 65), and mildly elevated calcium (10.6 mg/dL, reference range 6.8 to 10.5). That pattern triggered an endocrinology workup before anyone traced the numbers back to her supplement bottle. Stopping the biotin normalized the reported values within a month.³

That case illustrates the dose gap. Five milligrams is approximately 167 times the adult adequate intake. In NHANES 2015 to 2016, 2.8 percent of US adults reported taking at least 1 mg of biotin per day and 0.7 percent reported taking at least 5 mg per day. Among women aged 60 and older, the corresponding figures were 7.4 percent and 2.3 percent.¹² These are supplement-use estimates, not measured rates of assay interference.²

01How biotin supports metabolism

Biotin, also called vitamin B7, is a coenzyme for five carboxylase enzymes that handle fatty acid synthesis, amino acid breakdown, and gluconeogenesis. It is one of the B vitamins the body uses in small amounts for metabolic work. The adult adequate intake is 30 mcg per day, rising to 35 mcg during lactation, and eggs, nuts, seeds, salmon, sweet potatoes, and organ meats all supply biotin.¹ Gut bacteria also synthesize biotin.¹³

02Biotin deficiency is rare and has specific causes

True biotin deficiency occurs in specific situations. Biotinidase deficiency is a genetic condition screened for at birth in the United States. Long-term use of certain anticonvulsants such as phenytoin, carbamazepine, and primidone can lower biotin status. Heavy chronic alcohol use and eating large amounts of raw egg white over time, which contains avidin and binds biotin before it can be absorbed, are other documented risk factors.¹ Pregnancy can produce a marginal decline in biotin status, but its clinical significance is uncertain.¹

When deficiency does occur, reported signs include thinning hair and hair loss across the body, a scaly red rash concentrated around the eyes, nose, mouth, and perineum, conjunctivitis, ketolactic acidosis and aciduria, seizures, and skin infections.¹ Thinning hair alone is nonspecific and should not be used to diagnose biotin deficiency. Other causes, including thyroid function, iron status, and nutritional disorders, should be evaluated as clinically indicated.¹¹¹

03Biotin has little evidence for hair, skin, and nails

The case for biotin supplementation in healthy people rests on a small number of narrow studies. A case series of 45 people with brittle nails found firmer, harder nails in 41 of them after roughly 5.5 months on 2.5 mg per day, an uncontrolled result rather than a randomized trial.¹⁷ A separate small study found improved hair quality in children with uncombable hair syndrome, a rare structural hair condition, on 3 to 5 mg per day.⁷ A 2024 review found no difference between biotin and placebo in the highest-quality included hair-growth study. The other included studies examined specific populations and had important limitations.⁸ Broad hair-growth or nail-strength benefit in people without documented deficiency has not been established.⁷⁸

NIH has not set a tolerable upper intake level for biotin because no adverse effects have been reported from high intakes in humans. Laboratory interference remains a separate risk from high-dose supplements.¹

04Hair and nail products often contain megadoses

Some commercial hair, skin, and nail products provide biotin in milligram doses. AACC identifies doses of 5 mg or more as capable of interfering with some biotinylated immunoassays.⁹ Tracking NHANES data from 1999 through 2016, Li and colleagues found the share of US adults taking at least 1 mg per day rose from 0.1 percent to 2.8 percent, and the share taking at least 5 mg per day reached 0.7 percent by 2015 to 2016.² The increase concentrated in women, and especially older women: 7.4 percent of women 60 and older were taking at least 1 mg per day by the end of the study period, and 2.3 percent were taking at least 5 mg per day.² These supplement-use data do not measure how often laboratory assays were interfered with.

05Excess biotin interferes with immunoassay results

Many hormone and cardiac biomarker tests use a streptavidin-biotin bridge as part of how they capture and detect the substance being measured. Excess free biotin competes with biotinylated antibodies or antigens for streptavidin binding sites. The direction and magnitude of the error depend on the assay design and platform.⁵⁹¹⁰

In a sandwich assay, excess biotin can reduce signal and produce a falsely low result. In a competitive assay, excess biotin can increase signal and produce a falsely high result. The specific susceptibility varies by assay and platform.⁵⁹¹⁰

Common patterns on susceptible platforms include:⁵⁹¹⁰

These directions are common patterns, not universal rules. Check the current manufacturer's instructions for the platform used by the laboratory.⁹

06Biotin can distort troponin and thyroid tests

The FDA continues to receive adverse-event reports of falsely low troponin results in assays subject to biotin interference.⁴ A MAUDE report describes a patient taking biotin who had a low troponin result and later died, but the record does not establish that biotin caused the death or that the initial troponin was false.¹² Thyroid testing can show a falsely low TSH with a falsely high free T4 in susceptible assay designs, mimicking hyperthyroidism.⁵⁹¹⁰ Reproductive hormone and pregnancy tests can also be affected, depending on the platform.⁵⁹

07Stop biotin before bloodwork

Biotin's clearance depends on dose and kidney function. AACC summarizes an elimination half-life of about 2 hours at low concentrations and up to 18.8 hours after high doses. Daily dosing reaches steady state after roughly three days, and impaired renal function can delay clearance.⁹ Grimsey and colleagues modeled the relationship between dose, time since last dose, and immunoassay interference risk. After a 300 mg dose, their model estimated about 146 hours to fall below 20 ng/mL in the modeled population.⁶

For scheduled bloodwork, tell the ordering clinician and laboratory the exact product and dose, and follow their assay-specific instructions. If chest pain sends you to an emergency department, report biotin use immediately.⁴ When the clinical picture and troponin result do not match, clinicians should contact the laboratory and consider repeat testing or an assay that does not use biotin when interference is suspected.⁹

Check labels on products marketed for hair, skin, nails, energy, or prenatal support before bloodwork. Record the product, dose, and last time taken so the laboratory can assess possible interference.⁹

08References